BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125:292-7. [DOI: 10.1016/s0016-5085(03)00939-9] [Cited by in Crossref: 423] [Cited by in F6Publishing: 115] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Zoulim F. Emerging drugs for hepatitis B. Expert Opin Emerg Drugs 2007;12:199-217. [PMID: 17604497 DOI: 10.1517/14728214.12.2.199] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
2 Osiowy C, Villeneuve JP, Heathcote EJ, Giles E, Borlang J. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J Clin Microbiol. 2006;44:1994-1997. [PMID: 16757589 DOI: 10.1128/jcm.02477-05] [Cited by in Crossref: 52] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
3 Delaney WE 4th, Yang H, Miller MD, Gibbs CS, Xiong S. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob Agents Chemother 2004;48:3702-10. [PMID: 15388423 DOI: 10.1128/AAC.48.10.3702-3710.2004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
4 Kim KH, Kim ND, Seong BL. Discovery and development of anti-HBV agents and their resistance. Molecules. 2010;15:5878-5908. [PMID: 20802402 DOI: 10.3390/molecules15095878] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
5 Chotiyaputta W, Lok ASF. Hepatitis B virus variants. Nat Rev Gastroenterol Hepatol 2009;6:453-62. [DOI: 10.1038/nrgastro.2009.107] [Cited by in Crossref: 109] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
6 Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Arase Y, Ikeda K, Kumada H. Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine. J Gastroenterol 2007;42:368-74. [PMID: 17530361 DOI: 10.1007/s00535-007-2008-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
7 Kondo Y, Ueno Y, Shimosegawa T. Toll-like receptors signaling contributes to immunopathogenesis of HBV infection. Gastroenterol Res Pract. 2011;2011:810939. [PMID: 22190911 DOI: 10.1155/2011/810939] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
8 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother. 2013;57:6325-6332. [PMID: 24100506 DOI: 10.1128/aac.01742-13aac.01742-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Michailidis E, Kirby KA, Hachiya A, Yoo W, Hong SP, Kim SO, Folk WR, Sarafianos SG. Antiviral therapies: focus on hepatitis B reverse transcriptase. Int J Biochem Cell Biol. 2012;44:1060-1071. [PMID: 22531713 DOI: 10.1016/j.biocel.2012.04.006] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
10 Larrat S, Hilleret MN, Germi R, Lupo J, Nicod S, Zarski JP, Seigneurin JM, Morand P. Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs. Comp Hepatol 2008;7:3. [PMID: 18336716 DOI: 10.1186/1476-5926-7-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
11 Lee YB, Lee JH, Choi WM, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. Efficacy of adefovir-based combination therapy for patients with Lamivudine- and entecavir-resistant chronic hepatitis B virus infection. Antimicrob Agents Chemother 2013;57:6325-32. [PMID: 24100506 DOI: 10.1128/AAC.01742-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
12 Yeh CT, Chen T, Hsu CW, Chen YC, Lai MW, Liang KH, Chen TC. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer. 2011;11:398. [PMID: 21933446 DOI: 10.1186/1471-2407-11-398] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
13 Cuestas ML, Mathet VL, Oubiña JR, Sosnik A. Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection. Pharm Res 2010;27:1184-202. [PMID: 20333454 DOI: 10.1007/s11095-010-0112-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
14 Rybicka M, Stalke P, Dreczewski M, Smiatacz T, Bielawski KP. High-throughput matrix-assisted laser desorption ionization-time of flight mass spectrometry as an alternative approach to monitoring drug resistance of hepatitis B virus. J Clin Microbiol 2014;52:9-14. [PMID: 24068014 DOI: 10.1128/JCM.01891-13] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
15 Sayan M, Akhan SC, Senturk O. Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies. Hepat Mon 2011;11:835-42. [PMID: 22224083 DOI: 10.5812/kowsar.1735143X.775] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
16 Lam YF, Yuen MF, Seto WK, Lai CL. Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. Curr Hepat Rep. 2011;10:235-243. [PMID: 22131901 DOI: 10.1007/s11901-011-0109-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
17 Bourne C, Lee S, Venkataiah B, Lee A, Korba B, Finn MG, Zlotnick A. Small-molecule effectors of hepatitis B virus capsid assembly give insight into virus life cycle. J Virol 2008;82:10262-70. [PMID: 18684823 DOI: 10.1128/JVI.01360-08] [Cited by in Crossref: 93] [Cited by in F6Publishing: 52] [Article Influence: 6.6] [Reference Citation Analysis]
18 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
19 Sharon A, Chu CK. Understanding the molecular basis of HBV drug resistance by molecular modeling. Antiviral Res 2008;80:339-53. [PMID: 18765256 DOI: 10.1016/j.antiviral.2008.07.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
20 Pai SB, Bozdayi AM, Pai RB, Beker T, Sarioglu M, Turkyilmaz AR, Grier J, Yurdaydin C, Schinazi RF. Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy. Antimicrob Agents Chemother 2005;49:2618-24. [PMID: 15980328 DOI: 10.1128/AAC.49.7.2618-2624.2005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
21 Langley DR, Walsh AW, Baldick CJ, Eggers BJ, Rose RE, Levine SM, Kapur AJ, Colonno RJ, Tenney DJ. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992-4001. [PMID: 17267485 DOI: 10.1128/jvi.02395-06] [Cited by in Crossref: 125] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
22 Liu Y, Wang C, Zhong Y, Li X, Dai J, Ren X, Xu Z, Li L, Yao Z, Ji D, Wang L, Zhang L, Wong VW, Zoulim F, Xu D. Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection. J Viral Hepat 2011;18:e29-39. [PMID: 21392168 DOI: 10.1111/j.1365-2893.2010.01360.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
23 Ko SY, Kim BK, Kwon SY, Kim KH, Kim JH, Choe WH, Lee CH. Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment. World J Gastroenterol 2012; 18(44): 6437-6446 [PMID: 23197889 DOI: 10.3748/wjg.v18.i44.6437] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Ntziora F, Paraskevis D, Haida C, Magiorkinis E, Manesis E, Papatheodoridis G, Manolakopoulos S, Beloukas A, Chryssoy S, Magiorkinis G. Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology. J Clin Microbiol. 2009;47:2544-2550. [PMID: 19553583 DOI: 10.1128/JCM.00045-09] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
25 Kim JH, Jung YK, Joo MK, Kim JH, Yim HJ, Park JJ, Kim JS, Bak YT, Yeon JE, Byun KS. Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci 2010;25:257-64. [PMID: 20119580 DOI: 10.3346/jkms.2010.25.2.257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
26 Dehghani SM, Taghavi SA, Geramizadeh B, Nikeghbalian S, Derakhshan N, Malekpour A, Malek-Hosseini SA. Hepatitis B recurrence after liver transplantation: a single center experiences and review the literature. Hepat Mon. 2013;13:e6609. [PMID: 23483668 DOI: 10.5812/hepatmon.6609] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
27 Baumert TF, Thimme R, Weizsäcker FV. Pathogenesis of hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 82-90 [PMID: 17206757 DOI: 10.3748/wjg.v13.i1.82] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.0] [Reference Citation Analysis]
28 Kuwahara R, Kumashiro R, Ide T, Koga Y, Hino T, Hisamochi A, Tanaka K, Ogata K, Koga H, Takao Y. Predictive factors associated with the progression to hepatic failure caused by lamivudine-resistant HBV. Dig Dis Sci. 2008;53:2999-3006. [PMID: 18618250 DOI: 10.1007/s10620-008-0384-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Ha NB, Ha NB, Garcia RT, Trinh HN, Chaung KT, Nguyen HA, Nguyen KK, Levitt BS, Nguyen MH. Medication nonadherence with long-term management of patients with hepatitis B e antigen-negative chronic hepatitis B. Dig Dis Sci 2011;56:2423-31. [PMID: 21327918 DOI: 10.1007/s10620-011-1610-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
30 Pondé RA. Molecular mechanisms underlying HBsAg negativity in occult HBV infection. Eur J Clin Microbiol Infect Dis. 2015;34:1709-1731. [PMID: 26105620 DOI: 10.1007/s10096-015-2422-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
31 Yachimski P, Chung RT. Update on Hepatitis B and C Coinfection in HIV. Curr Infect Dis Rep. 2005;7:299-308. [PMID: 15963332 DOI: 10.1007/s11908-005-0063-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
32 Cassino L, Benetti S, Fay F, Tanno H, Quarleri J. Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations. BMC Infect Dis 2011;11:178. [PMID: 21696601 DOI: 10.1186/1471-2334-11-178] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
33 Qu B, Brown RJP. Strategies to Inhibit Hepatitis B Virus at the Transcript Level. Viruses 2021;13:1327. [PMID: 34372533 DOI: 10.3390/v13071327] [Reference Citation Analysis]
34 Margeridon-Thermet S, Shafer RW. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses. 2010;2:2696-2739. [PMID: 21243082 DOI: 10.3390/v2122696] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
35 Stalke P, Rybicka M, Wróblewska A, Dreczewski M, Stracewska E, Smiatacz T, Bielawski KP. An initial assessment of correlations between host- and virus-related factors affecting analogues antiviral therapy in HBV chronically infected patients. Med Sci Monit 2014;20:321-8. [PMID: 24569300 DOI: 10.12659/MSM.889788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10:1268-1275. [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
37 Klein MB, Baril JG, Charron MA, Fortin C, Lalonde R, Matte MF, Poliquin M, Talbot A, Therrien R, Tremblay C, Trottier B, Tsarevsky I, Villeneuve JP. Management and treatment of hepatitis B virus in patients with HIV infection: A practical guide for health care professionals. Can J Infect Dis Med Microbiol 2011;22:88-96. [PMID: 22942885 DOI: 10.1155/2011/686918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
38 Bang KB, Kim HJ. Management of antiviral drug resistance in chronic hepatitis B. World J Gastroenterol 2014; 20(33): 11641-11649 [PMID: 25206270 DOI: 10.3748/wjg.v20.i33.11641] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
39 Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079 [PMID: 17696224 DOI: 10.3748/wjg.v13.i30.4072] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
40 Mitsui F, Tsuge M, Kimura T, Kitamura S, Abe H, Saneto H, Kawaoka T, Miki D, Hatakeyama T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Takahashi S, Hayes CN, Igarashi H, Morimoto K, Shimizu M, Chayama K. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B. Antimicrob Agents Chemother 2010;54:3205-11. [PMID: 20498322 DOI: 10.1128/AAC.01372-09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS. No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrob Agents Chemother 2018;62:e01064-18. [PMID: 30038044 DOI: 10.1128/AAC.01064-18] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
42 Xu J, Wu B, Wang JH, Huang L, Wang DY, Zhao L, Zhao GP, Wang Y. Pre-existing mutations in reverse transcriptase of hepatitis B virus in treatment-naive Chinese patients with chronic hepatitis B. PLoS One. 2015;10:e0117429. [PMID: 25821965 DOI: 10.1371/journal.pone.0117429] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
43 Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol. 2012;2:353-365. [PMID: 25755457 DOI: 10.1016/j.jceh.2012.10.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.0] [Reference Citation Analysis]
44 Leemans W, Janssen H, de Man R. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13(18): 2554-2567 [PMID: 17552002 DOI: 10.3748/wjg.v13.i18.2554] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
45 Brunelle MN, Lucifora J, Neyts J, Villet S, Holy A, Trepo C, Zoulim F. In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants. Antimicrob Agents Chemother. 2007;51:2240-2243. [PMID: 17371827 DOI: 10.1128/aac.01440-06] [Cited by in Crossref: 29] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
46 Ramachandran S, Zhai X, Thai H, Campo DS, Xia G, Ganova-Raeva LM, Drobeniuc J, Khudyakov YE. Evaluation of intra-host variants of the entire hepatitis B virus genome. PLoS One 2011;6:e25232. [PMID: 21949887 DOI: 10.1371/journal.pone.0025232] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
47 Jacquard AC, Brunelle MN, Pichoud C, Durantel D, Carrouée-Durantel S, Trepo C, Zoulim F. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2’,3’-dideoxy-3’-fluoroguanosine. Antimicrob Agents Chemother. 2006;50:955-961. [PMID: 16495257 DOI: 10.1128/aac.50.3.955-961.2006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
48 Jiang Y, Ma Z, Xin G, Yan H, Li W, Xu H, Hao C, Niu J, Zhao P. Th1 and Th2 immune response in chronic hepatitis B patients during a long-term treatment with adefovir dipivoxil. Mediators Inflamm. 2010;2010:143026. [PMID: 21127728 DOI: 10.1155/2010/143026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
49 Ratziu V, Thibault V, Benhamou Y, Poynard T. Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant. Comp Hepatol. 2006;5:1. [PMID: 16405720 DOI: 10.1186/1476-5926-5-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
50 Schildgen O, Olotu C, Funk A, Zöllner B, Helm M, Rockstroh JK, Sirma H. Selection and counterselection of the rtI233V adefovir resistance mutation during antiviral therapy. J Clin Microbiol. 2010;48:631-634. [PMID: 20007398 DOI: 10.1128/jcm.01073-09] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
51 Thai H, Campo DS, Lara J, Dimitrova Z, Ramachandran S, Xia G, Ganova-Raeva L, Teo CG, Lok A, Khudyakov Y. Convergence and coevolution of hepatitis B virus drug resistance. Nat Commun. 2012;3:789. [PMID: 22510694 DOI: 10.1038/ncomms1794] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
52 Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2:147-151. [PMID: 19669299 DOI: 10.1007/s12072-008-9048-3] [Cited by in Crossref: 99] [Cited by in F6Publishing: 99] [Article Influence: 7.1] [Reference Citation Analysis]
53 Menne S, Butler SD, George AL, Tochkov IA, Zhu Y, Xiong S, Gerin JL, Cote PJ, Tennant BC. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2008;52:3617-3632. [PMID: 18676881 DOI: 10.1128/aac.00654-08] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
54 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol 2008; 14(45): 6902-6910 [PMID: 19058323 DOI: 10.3748/wjg.14.6902] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
56 Menne S, Cote PJ, Korba BE, Butler SD, George AL, Tochkov IA, Delaney WE, Xiong S, Gerin JL, Tennant BC. Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005;49:2720-2728. [PMID: 15980342 DOI: 10.1128/aac.49.7.2720-2728.2005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
57 Yan J, Xie W, Wang L, Wang JB, Feng X, Song SJ, Liu SA, Wei HS. Application of nest PCR-RFLP in the detection of adefovir dipivoxil resistance-associated mutation in hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2006; 14(7): 714-717 [DOI: 10.11569/wcjd.v14.i7.714] [Reference Citation Analysis]
58 Huang KL, Lai YK, Lin CC, Chang JM. Inhibition of hepatitis B virus production by Boehmeria nivea root extract in HepG2 2.2.15 cells. World J Gastroenterol 2006; 12(35): 5721-5725 [PMID: 17007029 DOI: 10.3748/wjg.v12.i35.5721] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
59 Song ZL, Cui YJ, Zheng WP, Teng DH, Zheng H. Diagnostic and therapeutic progress of multi-drug resistance with anti-HBV nucleos(t)ide analogues. World J Gastroenterol 2012; 18(48): 7149-7157 [PMID: 23326119 DOI: 10.3748/wjg.v18.i48.7149] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
60 Schildgen V, Ziegler S, Tillmann RL, Schildgen O. Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case. Virol J 2010;7:167. [PMID: 20646332 DOI: 10.1186/1743-422X-7-167] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
61 Okanoue T, Minami M. Update of research and management of hepatitis B. J Gastroenterol 2006;41:107-18. [PMID: 16568369 DOI: 10.1007/s00535-006-1774-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
62 Kondo Y, Ueno Y, Shimosegawa T. Immunopathogenesis of hepatitis B persistent infection: implications for immunotherapeutic strategies. Clin J Gastroenterol 2009;2:71-9. [PMID: 26192169 DOI: 10.1007/s12328-009-0074-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
63 Wightman F, Walters T, Ayres A, Bowden S, Bartholomeusz A, Lau D, Locarnini S, Lewin SR. Comparison of sequence analysis and a novel discriminatory real-time PCR assay for detection and quantification of Lamivudine-resistant hepatitis B virus strains. J Clin Microbiol. 2004;42:3809-3812. [PMID: 15297535 DOI: 10.1128/jcm.42.8.3809-3812.2004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
64 Osborn MK. Safety and efficacy of telbivudine for the treatment of chronic hepatitis B. Ther Clin Risk Manag 2009;5:789-98. [PMID: 19851526 DOI: 10.2147/tcrm.s5318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
65 Hui CK, Lau GK. Advances in immunomodulating therapy of HBV infection. Int J Med Sci 2005;2:24-9. [PMID: 15968336 DOI: 10.7150/ijms.2.24] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
66 Fujisaki S, Yokomaku Y, Shiino T, Koibuchi T, Hattori J, Ibe S, Iwatani Y, Iwamoto A, Shirasaka T, Hamaguchi M. Outbreak of infections by hepatitis B virus genotype A and transmission of genetic drug resistance in patients coinfected with HIV-1 in Japan. J Clin Microbiol. 2011;49:1017-1024. [PMID: 21248087 DOI: 10.1128/jcm.02149-10] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
67 Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011;4:55-64. [PMID: 21694909 DOI: 10.2147/idr.s4188] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
68 Buti M, Castells L. Prevention and treatment of hepatitis B virus recurrence after liver transplantation: . Current Opinion in Organ Transplantation 2006;11:589-93. [DOI: 10.1097/mot.0b013e3280102b22] [Reference Citation Analysis]
69 Zhang ZH, Wu CC, Chen XW, Li X, Li J, Lu MJ. Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol 2016; 22(1): 126-144 [PMID: 26755865 DOI: 10.3748/wjg.v22.i1.126] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 49] [Article Influence: 10.0] [Reference Citation Analysis]
70 Wang MR, Li P. Value of antiviral therapy in patients with hepatitis B virus-related liver failure. Shijie Huaren Xiaohua Zazhi 2011; 19(15): 1598-1603 [DOI: 10.11569/wcjd.v19.i15.1598] [Reference Citation Analysis]
71 Jung YK, Yeon JE, Han WS, Kim JH, Kim JH, Park JJ, Kim JS, Bak YT, Yoo W, Hong SP, Kim SO, Kwon SY, Byun KS, Lee CH. Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B. Gut Liver 2010;4:212-8. [PMID: 20559524 DOI: 10.5009/gnl.2010.4.2.212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Yamada N, Sugiyama R, Nitta S, Murayama A, Kobayashi M, Okuse C, Suzuki M, Yasuda K, Yotsuyanagi H, Moriya K, Koike K, Wakita T, Kato T. Resistance mutations of hepatitis B virus in entecavir-refractory patients. Hepatol Commun 2017;1:110-21. [PMID: 29404449 DOI: 10.1002/hep4.1022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
73 Kobashi H, Fujioka S, Kawaguchi M, Kumada H, Yokosuka O, Hayashi N, Suzuki K, Okanoue T, Sata M, Tsubouchi H, Sato C, Kiyosawa K, Tanikawa K, Seriu T, Ishikawa H, Takaki A, Iwasaki Y, Osawa T, Takaki T, Sakaguchi K, Shiratori Y, Yamamoto K, Tenney DJ, Omata M. Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B. Hepatol Int 2009;3:403-10. [PMID: 19669367 DOI: 10.1007/s12072-008-9108-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
74 Seley-Radtke KL, Yates MK. The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold. Antiviral Res 2018;154:66-86. [PMID: 29649496 DOI: 10.1016/j.antiviral.2018.04.004] [Cited by in Crossref: 146] [Cited by in F6Publishing: 108] [Article Influence: 36.5] [Reference Citation Analysis]
75 McClure CP, Urbanowicz RA, King BJ, Cano-Crespo S, Tarr AW, Ball JK. Flexible and rapid construction of viral chimeras applied to hepatitis C virus. J Gen Virol 2016;97:2187-93. [PMID: 27329374 DOI: 10.1099/jgv.0.000530] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
76 Wang Y, Liu S, Chen Y, Zheng S, Zhou L, Lu F, Duan Z. Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. Int J Med Sci 2015;12:416-22. [PMID: 26005376 DOI: 10.7150/ijms.11687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
77 Han SH. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B. Drugs 2006;66:1831-51. [PMID: 17040114 DOI: 10.2165/00003495-200666140-00005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
78 Yatsuji H, Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif. Antimicrob Agents Chemother. 2006;50:3867-3874. [PMID: 16982790 DOI: 10.1128/aac.00239-06] [Cited by in Crossref: 51] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
79 Yim HJ, Hwang SG. Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade. Clin Mol Hepatol. 2013;19:195-209. [PMID: 24133659 DOI: 10.3350/cmh.2013.19.3.195] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
80 Sherman M, Bain V, Villeneuve JP, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol 2004;15:313-26. [PMID: 18159509 DOI: 10.1155/2004/326964] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
81 Kim SS, Cheong JY, Cho SW. Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B. Gut Liver 2011;5:278-87. [PMID: 21927654 DOI: 10.5009/gnl.2011.5.3.278] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
82 Rodriguez-Frias F, Buti M, Tabernero D, Homs M. Quasispecies structure, cornerstone of hepatitis B virus infection: Mass sequencing approach. World J Gastroenterol 2013; 19(41): 6995-7023 [PMID: 24222943 DOI: 10.3748/wjg.v19.i41.6995] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.2] [Reference Citation Analysis]
83 Sinn DH, Lee HI, Gwak GY, Choi MS, Koh KC, Paik SW, Yoo BC, Lee JH. Virological response to adefovir monotherapy and the risk of adefovir resistance. World J Gastroenterol 2011; 17(30): 3526-3530 [PMID: 21941420 DOI: 10.3748/wjg.v17.i30.3526] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
84 Ono-Nita SK, Carrilho FJ, Cardoso RA, Nita ME, da Silva LC. Searching for chronic hepatitis B patients in a low prevalence area--role of racial origin. BMC Fam Pract 2004;5:7. [PMID: 15084223 DOI: 10.1186/1471-2296-5-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
85 Yu LH, Li N, Cheng SQ. The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma. Int J Hepatol. 2011;2011:416459. [PMID: 21994855 DOI: 10.4061/2011/416459] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
86 Li J, Du Y, Liu X, Shen QC, Huang AL, Zheng MY, Luo XM, Jiang HL. Binding sensitivity of adefovir to the polymerase from different genotypes of HBV: molecular modeling, docking and dynamics simulation studies. Acta Pharmacol Sin 2013;34:319-28. [PMID: 23202802 DOI: 10.1038/aps.2012.146] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
87 Li X, Wang L, Zhong Y, Wong VW, Xu Z, Liu Y, Li Q, Xin S, Zhao J, Xu D. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol. 2010;48:4363-4369. [PMID: 20881176 DOI: 10.1128/jcm.01518-10] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
88 Anderson AL, Banks KE, Pontoglio M, Yaniv M, McLachlan A. Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice. J Virol. 2005;79:11045-11052. [PMID: 16103155 DOI: 10.1128/jvi.79.17.11045-11052.2005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
89 Wong DK, Tsoi O, Huang FY, Seto WK, Fung J, Lai CL, Yuen MF. Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus. J Clin Microbiol 2014;52:3209-15. [PMID: 24951803 DOI: 10.1128/JCM.00343-14] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
90 Sablon E, Shapiro F. Advances in Molecular Diagnosis of HBV Infection and Drug Resistance. Int J Med Sci. 2005;2:8-16. [PMID: 15968334 DOI: 10.7150/ijms.2.8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
91 Njei B, Kumar S, Kongnyuy EJ; Cochrane Hepato-Biliary Group. Adefovir dipivoxil for chronic hepatitis B. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd009521] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
92 Lim YS. Management of Antiviral Resistance in Chronic Hepatitis B. Gut Liver 2017;11:189-95. [PMID: 28183162 DOI: 10.5009/gnl15562] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
93 Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007;356:1445-1454. [PMID: 17409326 DOI: 10.1056/nejmra065142] [Cited by in Crossref: 195] [Cited by in F6Publishing: 87] [Article Influence: 13.0] [Reference Citation Analysis]
94 Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology. 2009;49:S174-S184. [PMID: 19399794 DOI: 10.1002/hep.22900] [Cited by in Crossref: 142] [Cited by in F6Publishing: 140] [Article Influence: 10.9] [Reference Citation Analysis]
95 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
96 Jun CH, Hong HJ, Chung MW, Park SY, Cho SB, Park CH, Joo YE, Kim HS, Choi SK, Rew JS. Risk factors for hepatocellular carcinoma in patients with drug-resistant chronic hepatitis B. World J Gastroenterol 2013; 19(40): 6834-6841 [PMID: 24187458 DOI: 10.3748/wjg.v19.i40.6834] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
97 Lim YS, Suh DJ. Current antiviral therapy for chronic hepatitis B. J Korean Med Sci. 2004;19:489-494. [PMID: 15308835 DOI: 10.3346/jkms.2004.19.4.489] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
98 Pallier C, Rodriguez C, Brillet R, Nordmann P, Hézode C, Pawlotsky JM. Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009;49:50-9. [PMID: 19065672 DOI: 10.1002/hep.22634] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
99 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(4): 543-545 [DOI: 10.11569/wcjd.v13.i4.543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
100 Lampertico P, Aghemo A, Viganò M, Colombo M. HBV and HCV therapy. Viruses 2009;1:484-509. [PMID: 21994557 DOI: 10.3390/v1030484] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
101 Li W, Warner N, Sozzi V, Yuen L, Colledge D, Li T, Zhuang H, Locarnini S, Revill PA. Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. Hepatol Int 2013;7:443-50. [PMID: 26201776 DOI: 10.1007/s12072-012-9411-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
102 Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller MD. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother. 2006;50:2471-2477. [PMID: 16801428 DOI: 10.1128/aac.00138-06] [Cited by in Crossref: 172] [Cited by in F6Publishing: 70] [Article Influence: 10.8] [Reference Citation Analysis]
103 Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants. J Virol 2004;78:8524-35. [PMID: 15280461 DOI: 10.1128/JVI.78.16.8524-8535.2004] [Cited by in Crossref: 84] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
104 Malik A, Singhal DK, Albanyan A, Husain SA, Kar P. Hepatitis B virus gene mutations in liver diseases: a report from New Delhi. PLoS One. 2012;7:e39028. [PMID: 22720023 DOI: 10.1371/journal.pone.0039028] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
105 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48:3498-3507. [PMID: 15328117 DOI: 10.1128/aac.48.9.3498-3507.2004] [Cited by in Crossref: 407] [Cited by in F6Publishing: 120] [Article Influence: 22.6] [Reference Citation Analysis]
106 Karayiannis P. Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) 2012;2012:478631. [PMID: 24278700 DOI: 10.6064/2012/478631] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
107 Gupta N, Goyal M, Wu CH, Wu GY. The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs. J Clin Transl Hepatol. 2014;2:202-211. [PMID: 26357626 DOI: 10.14218/jcth.2014.00021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
108 Gao Z, Liu FJ, Liu L, Zhou TY, Lei J, Xu L, Liu C, Dai J, Chen EQ, Tang H. Application of hepatitis B virus replication mouse model. World J Gastroenterol 2010; 16(16): 1979-1985 [PMID: 20419834 DOI: 10.3748/wjg.v16.i16.1979] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
109 Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and clinical implications. Infect Dis Clin North Am 2010;24:413-37. [PMID: 20466277 DOI: 10.1016/j.idc.2010.01.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 55] [Article Influence: 6.2] [Reference Citation Analysis]
110 Yeon JE, Yoo W, Hong SP, Chang YJ, Yu SK, Kim JH, Seo YS, Chung HJ, Moon MS, Kim SO. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006;55:1488-1495. [PMID: 16461777 DOI: 10.1136/gut.2005.077099] [Cited by in Crossref: 158] [Cited by in F6Publishing: 144] [Article Influence: 9.9] [Reference Citation Analysis]
111 Zhang JX, Lang JF, Liu YN. Combination therapy of lamivudine and hepatitis B vaccine for chronic hepatitis B: an analysis of 39 cases. Shijie Huaren Xiaohua Zazhi 2009; 17(6): 614-617 [DOI: 10.11569/wcjd.v17.i6.614] [Reference Citation Analysis]
112 Osborn MK, Han SH, Regev A, Bzowej NH, Ishitani MB, Tran TT, Lok AS. Outcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting list. Clin Gastroenterol Hepatol. 2007;5:1454-1461. [PMID: 17977800 DOI: 10.1016/j.cgh.2007.08.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
113 Ebata S, Hashimoto S, Suzuki A, Ito M, Maoka T, Ishikawa Y, Mochizuki T, Koike T. A case of adefovir-induced membranous nephropathy related to hepatitis B caused by lamivudine-resistant virus after liver transplant due to Byler's disease. Clin Exp Nephrol 2012;16:805-10. [PMID: 22911115 DOI: 10.1007/s10157-012-0680-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
114 Wang W, Shu Y, Bao H, Zhao W, Wang W, Wang Q, Lei X, Cui D, Yan Z. Genotypes and Hot Spot Mutations of Hepatitis B Virus in Northwest Chinese Population and Its Correlation with Diseases Progression. Biomed Res Int 2019;2019:3890962. [PMID: 31886206 DOI: 10.1155/2019/3890962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
115 Choo H, Beadle JR, Kern ER, Prichard MN, Keith KA, Hartline CB, Trahan J, Aldern KA, Korba BE, Hostetler KY. Antiviral activities of novel 5-phosphono-pent-2-en-1-yl nucleosides and their alkoxyalkyl phosphonoesters. Antimicrob Agents Chemother 2007;51:611-5. [PMID: 17130297 DOI: 10.1128/AAC.00444-06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Tillmann HL. Antiviral therapy and resistance with hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 125-140 [PMID: 17206760 DOI: 10.3748/wjg.v13.i1.125] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]